Recruiting
Phase 3

Lucentis

Sponsor:

The New York Eye & Ear Infirmary

Code:

NCT01255774

Conditions

Age Related Macular Degeneration

Eligibility Criteria

Sex: All

Age: 51 - 70+

Healthy Volunteers: Not accepted

Interventions

ranibizumab

Study Details

Brief summary:

The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on the strong correlation between VEGF levels in aqueous and vitreous humor and active blood vessel formation. LucentisTM has been shown to maintain or improve vision in wet AMD. Since the treatments do not halt the loss of visual acuity in wet AMD, it is important to accurately measure anatomic response to treatments thereby enhancing the ability to understand patterns of response and predict the necessity for continued therapy.

Conditions

Age Related Macular Degeneration

Study ID

NCT01255774

Start date

Jun, 2007

Status verified date

Dec, 2011

Completion date

Dec, 2012

Anticipated

Primary completion date

Dec, 2012

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 51 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Subjects of either gender, Age > 50 years
  • Best corrected visual acuity in the study eye between 20/40 and 20/320.
  • Subfoveal choroidal neovascularization, secondary to age related macular degeneration.
  • Any subretinal hemorrhage must comprise no more than 50% of total lesion size.
  • Clear ocular media and adequate papillary dilation to permit good quality stereoscopic fundus photography
  • Men must use barrier contraception or abstinence throughout the study.
  • Ability to return for all study visits

Exclusion Criteria:

  • Had ocular surgery within the past 60 days in the study eye.
  • Had previous refractive eye surgery (RK, PRK, LASIK, ALK, etc.) within the past 3 months for the study eye.
  • Has intraocular pressure ≥ 25 mmHg in the study eye.
  • Has posterior uveitis in the study eye.
  • Has ongoing infection in the study eye.
  • Has retinal or optic nerve disease that could independently affect visual acuity including high axial myopia (>-8.00 D) and diabetic retinopathy in the study eye.
  • Has anterior segment and vitreous abnormalities that would preclude adequate observation of the fundus for photographs and fluorescein angiography in the study eye.
  • Has received investigational therapy within 60 days prior to study entry.
  • Has been previously enrolled in or previous treatment with MSI-1256F for injection.
  • Has received prior approved treatment for subfoveal CNV within 60 days to study entry.
  • Has clinically uncontrolled diabetes mellitus.
  • Has other condition the investigator considers to be sound reasons for exclusion (e.g., lack of motivation, history of poor compliance, concomitant illnesses, personality disorder, mental condition, drug abuse, use of neuroleptics, physical or social condition predicting difficulty in long-term follow-up).
  • Has an allergy to sodium fluorescein dye.
  • Currently uses systemic or topical medications known to be toxic to the retina, lens, or optic nerve, such as deferoxamine, chloroquine/hydrochloroquine, tamoxifen, chlorpromazine, phenothiazines, steroids and ethambutol.
  • Pregnancy (positive pregnancy test) or lactation
  • Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Ranibizumab

Open Label use of Ranibizumab for wet age related macular degeneration

Interventions

ranibizumab

An open-label, study of intravitreally administered ranibizumab

Primary outcome measure

  • Central retinal thickness [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Katy W Tai, CCRC

212-979-4251ktai@nyee.edu

Locations

New York Eye and Ear Infirmary

Recruiting

New York, New York, United States, 10003

Contacts

Katy W Tai, CCRC

212-979-4251ktai@nyee.edu

More Information

Sponsor

The New York Eye & Ear Infirmary

Last update posted

Dec 5, 2011

Last verified

Dec, 2011

Keywords

  • subfoveal CNV
  • Wet (Exudative) AMD
  • macular degeneration

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by The New York Eye & Ear Infirmary on 2011-12-05.